CTOs on the Move

Easton Pharmaceuticals

www.eastonpharmaceuticalsinc.com

 
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries such as medical marijuana. The Company previously developed and owned an FDA approved wound-healing drug and currently owns topically delivered drugs to treat cancer and other conditions that are all in various stages of development and approval. Easton has entered into a 50 / 50 revenue sharing agreement towards being the exclusive distributor in Mexico and Latin America for patented women`s diagnostic products and two generic cancer products. Easton has completed an acquisition that grants 40% ownership interest in Medicated Markets International LLC; ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Secura Bio

Secura Bio™ is a pharmaceutical company committed to giving patients access to innovative therapies. Headquartered in Henderson, Nevada, Secura Bio™ has operations in the U.S. and Offices in San Diego.

Cedarburg Hauser Pharmaceuticals

Cedarburg Pharmaceuticals delivers unsurpassed value in the development and manufacturing of commercial and clinical APIs. We believe value is more than just price. Value means making your life simpler. Our process development, scale-up, commercial

Sierra By The Sea

Sierra by the Sea is a beachfront residential drug addiction rehab & mental health treatment facility. Offering evidence-based addiction treatment for adults.

Northstar RX

Northstar RX is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Graybug Vision

Every day, Graybug Vision works relentlessly to make healthy vision more accessible and more manageable for patients with chronic vision-threatening eye diseases. We are a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of chronic diseases of the retina and optic nerve. Our novel technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12 months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical outcomes.